AU2004285962A1 - 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease - Google Patents

1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease Download PDF

Info

Publication number
AU2004285962A1
AU2004285962A1 AU2004285962A AU2004285962A AU2004285962A1 AU 2004285962 A1 AU2004285962 A1 AU 2004285962A1 AU 2004285962 A AU2004285962 A AU 2004285962A AU 2004285962 A AU2004285962 A AU 2004285962A AU 2004285962 A1 AU2004285962 A1 AU 2004285962A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
formulation
myhc
pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004285962A
Other languages
English (en)
Inventor
Larry Melvin
Kathy Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Colorado Inc
Original Assignee
Myogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myogen Inc filed Critical Myogen Inc
Publication of AU2004285962A1 publication Critical patent/AU2004285962A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004285962A 2003-11-03 2004-11-03 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease Abandoned AU2004285962A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51721703P 2003-11-03 2003-11-03
US60/517,217 2003-11-03
PCT/US2004/036569 WO2005042487A1 (fr) 2003-11-03 2004-11-03 Composes1,4-dihydropyridine, compositions pharmaceutiques et methodes de traitement des maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
AU2004285962A1 true AU2004285962A1 (en) 2005-05-12

Family

ID=34549595

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004285962A Abandoned AU2004285962A1 (en) 2003-11-03 2004-11-03 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease

Country Status (9)

Country Link
US (1) US20050124634A1 (fr)
EP (1) EP1685108B1 (fr)
JP (1) JP2007510728A (fr)
AT (1) ATE402147T1 (fr)
AU (1) AU2004285962A1 (fr)
CA (1) CA2544772A1 (fr)
DE (1) DE602004015321D1 (fr)
IL (1) IL175357A0 (fr)
WO (1) WO2005042487A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634437A1 (fr) * 2005-12-20 2007-07-05 Gilead Colorado, Inc. Composes de 4,7-dihydrothieno¬2,3-b|pyridine et compositions pharmaceutiques
MX2011012043A (es) * 2009-05-13 2012-03-29 Protein Delivery Solutions Llc Sistema farmaceutico para suministro transmembrana.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920225A (en) * 1986-12-22 1990-04-24 Laboratoires Syntex S.A. Resolution of 1,4-dihydropyridine derivatives
TW215434B (fr) * 1992-03-07 1993-11-01 Hoechst Ag
KR20040072733A (ko) * 2002-01-18 2004-08-18 바이탈 말리아 사이언티픽 리서치 파운데이션 칼슘채널 차단제로서의 1,4-디하이드로피리딘 및 피리딘화합물
ATE404200T1 (de) * 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen

Also Published As

Publication number Publication date
US20050124634A1 (en) 2005-06-09
CA2544772A1 (fr) 2005-05-12
EP1685108A1 (fr) 2006-08-02
EP1685108B1 (fr) 2008-07-23
JP2007510728A (ja) 2007-04-26
ATE402147T1 (de) 2008-08-15
IL175357A0 (en) 2006-09-05
WO2005042487A1 (fr) 2005-05-12
DE602004015321D1 (de) 2008-09-04

Similar Documents

Publication Publication Date Title
US20070015777A1 (en) Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
EP3746081A1 (fr) Nouvelles utilisations
US9446023B2 (en) Methods and compositions involving (S)-bucindolol
US20060018970A1 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
US7638519B2 (en) Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
US20060030611A1 (en) Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
US7485653B2 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
EP2593099A1 (fr) Wogonine utilisée pour prévenir et traiter une hypertrophie cardiaque
EP1685108B1 (fr) Composes1,4-dihydropyridine, compositions pharmaceutiques et methodes de traitement des maladies cardiovasculaires
US9456997B2 (en) Selective inhibition of β1-adrenergic receptors for the treatment of pediatric heart failure
US20060025463A1 (en) Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
MXPA06004946A (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application